https://www.pharmaradar360.com/article/form-144-collegium-pharmaceutical-for-17-july-by-investing-com-66001307ac5ac730Pharma Surgeen2026-07-17T16:18:38.000ZForm 144 COLLEGIUM PHARMACEUTICAL For: 17 July By Investing.comhttps://www.pharmaradar360.com/article/bright-path-congratulates-khona-scientific-s-investment-in-strengthening-america-0aa364be1801c381Pharma Surgeen2026-07-17T16:11:00.000ZBRIGHT PATH CONGRATULATES KHONA SCIENTIFIC'S INVESTMENT In STRENGTHENING AMERICA'S PHARMACEUTICAL SUPPLY CHAINhttps://www.pharmaradar360.com/article/jcvi-statement-on-meningococcal-b-vaccination-in-older-children-and-young-adults-26c1361f3a11f5e2Pharma Surgeen2026-07-17T16:05:32.000ZJCVI statement on meningococcal B vaccination in older children and young adults, 16 July 2026https://www.pharmaradar360.com/article/china-pharmaceutical-innovation-conference-cpic-e98a3a26c3a5f307Pharma Surgeen2026-07-17T16:05:14.000ZChina Pharmaceutical Innovation Conference (CPIC)https://www.pharmaradar360.com/article/fda-raised-conflict-of-interest-concerns-ahead-of-new-peptide-panel-0d05f6525b915b02Pharma Surgeen2026-07-17T16:00:00.000ZFDA raised conflict of interest concerns ahead of new peptide panelhttps://www.pharmaradar360.com/article/study-expects-plasticware-use-to-increase-7e265d7c915fb457Pharma Surgeen2026-07-17T15:45:05.000ZStudy expects plasticware use to increasehttps://www.pharmaradar360.com/article/cloudbreak-pharma-inc-announces-completion-of-safety-review-by-the-fda-for-cbt-3-65f368ad47aec419Pharma Surgeen2026-07-17T15:40:56.000ZCloudbreak Pharma Inc. Announces Completion Of Safety Review By The FDA For CBT-358 Investigational New Drug Applicationhttps://www.pharmaradar360.com/article/raphael-pharmaceutical-inc-announces-chief-financial-officer-changes-effective-j-f0946ad798ec907ePharma Surgeen2026-07-17T15:36:53.000ZRaphael Pharmaceutical Inc. Announces Chief Financial Officer Changes, Effective July 16, 2026https://www.pharmaradar360.com/article/bio-san-diego-2026-executive-interviews-e07fc300cca2c9a5Pharma Surgeen2026-07-17T15:18:59.000ZBIO San Diego 2026 Executive Interviewshttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-963ee016ca25eb9dPharma Surgeen2026-07-17T15:09:49.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-00ac63488b85ac4aPharma Surgeen2026-07-17T15:02:46.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/guidance-medical-devices-list-of-uk-approved-bodies-a9ce4e9e06b7ac08Pharma Surgeen2026-07-17T15:02:34.000ZGuidance: Medical devices: list of UK approved bodieshttps://www.pharmaradar360.com/article/jasper-therapeutics-3b41362289520222Pharma Surgeen2026-07-17T14:57:45.000ZJasper Therapeuticshttps://www.pharmaradar360.com/article/what-teva-pharmaceutical-industries-teva-s-tev-408-vitiligo-data-and-funding-dea-c66895e4ea971a27Pharma Surgeen2026-07-17T14:55:19.000ZWhat Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholdershttps://www.pharmaradar360.com/article/ion-pair-reagents-market-growth-trajectory-to-2035-analytical-chemistry-demand-a-164f5c4b721864f5Pharma Surgeen2026-07-17T14:51:12.000ZIon-Pair Reagents Market Growth Trajectory to 2035: Analytical Chemistry Demand Accelerates - News and Statisticshttps://www.pharmaradar360.com/article/the-end-for-gsk-s-chronic-cough-treatment-e2d9feb7b026c38ePharma Surgeen2026-07-17T14:45:26.000ZThe end for GSK’s chronic cough treatmenthttps://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-covered-by-pcv13-2ddf38f53562a4bdPharma Surgeen2026-07-17T14:41:58.000ZPneumococcal disease: cases caused by serotypes covered by PCV13https://www.pharmaradar360.com/article/pneumococcal-disease-cases-caused-by-serotypes-not-covered-by-pcv13-ce6e5496ced9fd89Pharma Surgeen2026-07-17T14:29:51.000ZPneumococcal disease: cases caused by serotypes not covered by PCV13https://www.pharmaradar360.com/article/50-shades-of-legally-gray-fda-s-juicy-peptide-cliffhanger-70f0114cfd08d7d0Pharma Surgeen2026-07-17T14:07:55.000Z50 Shades of Legally Gray: FDA’s Juicy Peptide Cliffhangerhttps://www.pharmaradar360.com/article/new-effort-can-help-beat-china-in-biotech-race-if-rfk-jr-doesn-t-hold-it-back-71911de930d1a63ePharma Surgeen2026-07-17T14:00:00.000ZNew effort can help beat China in biotech race — if RFK Jr. doesn’t hold it backhttps://www.pharmaradar360.com/article/inside-the-uk-us-pharmaceutical-supply-chain-deal-b8434d602ad0e1acPharma Surgeen2026-07-17T13:56:12.000ZInside the UK-US Pharmaceutical Supply Chain Dealhttps://www.pharmaradar360.com/article/j-j-s-mark-graham-on-advancing-nipocalimab-as-treatment-for-sle-a3cabf9419b3297aPharma Surgeen2026-07-17T13:55:20.000ZJ&J’s Mark Graham on advancing nipocalimab as treatment for SLEhttps://www.pharmaradar360.com/article/jasper-finds-new-purpose-in-merger-with-kira-while-offloading-tavneos-rival-to-m-a0e76b7dac6e6068Pharma Surgeen2026-07-17T13:54:16.000ZJasper finds new purpose in merger with Kira, while offloading Tavneos rival to Miradorhttps://www.pharmaradar360.com/article/tagrisso-chasing-blossomhill-enters-nasdaq-queue-as-biotech-ipos-flourish-4ceaf0792f5699d3Pharma Surgeen2026-07-17T13:54:00.000ZTagrisso-chasing BlossomHill enters Nasdaq queue as biotech IPOs flourishhttps://www.pharmaradar360.com/article/apha-urges-fda-to-put-patient-safety-first-in-review-of-peptide-substances-d81ff3322f9c1474Pharma Surgeen2026-07-17T13:48:00.000ZAPhA urges FDA to put patient safety first in review of peptide substanceshttps://www.pharmaradar360.com/article/health-news-round-up-vaccination-testosterone-and-neighbourhood-health-935f9761f60cb940Pharma Surgeen2026-07-17T13:42:37.000ZHealth news round-up: vaccination, testosterone and neighbourhood healthhttps://www.pharmaradar360.com/article/weekly-rundown-biogen-pushes-anti-tau-drug-into-phase-3-after-endpoint-miss-6524dfa1fdbd8a5ePharma Surgeen2026-07-17T13:42:25.000ZWeekly Rundown: Biogen pushes anti-tau drug into Phase 3 after endpoint misshttps://www.pharmaradar360.com/article/fierce-pharma-asia-gsk-merck-adcs-trial-wins-az-s-1-5b-egfr-buy-biotechs-new-pat-32358f6a5cd363c9Pharma Surgeen2026-07-17T13:38:37.000ZFierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent trickshttps://www.pharmaradar360.com/article/mumbai-s-110-year-old-parsi-dairy-farm-loses-food-licence-after-fda-inspection-44c462fe10297f77Pharma Surgeen2026-07-17T13:31:12.000ZMumbai's 110-Year-Old Parsi Dairy Farm Loses Food Licence After FDA Inspectionhttps://www.pharmaradar360.com/article/update-van-het-document-over-goedkeuringsdatum-van-variaties-hernieuwingen-en-no-316da521f93d2cefPharma Surgeen2026-07-17T13:26:53.000ZUpdate van het document over goedkeuringsdatum van variaties, hernieuwingen en notificaties bij geneesmiddelen voor menselijk gebruikhttps://www.pharmaradar360.com/article/johnson-johnson-to-spend-up-to-750m-restructuring-pharmaceutical-supply-chain-16f5f8bbb2d31d80Pharma Surgeen2026-07-17T13:26:01.000ZJohnson & Johnson to spend up to $750m restructuring pharmaceutical supply chainhttps://www.pharmaradar360.com/article/raphael-pharmaceutical-raph-names-new-cfo-as-chairman-and-cfo-resign-8b40754c5eea7706Pharma Surgeen2026-07-17T13:21:23.000ZRaphael Pharmaceutical (RAPH) names new CFO as chairman and CFO resignhttps://www.pharmaradar360.com/article/biotech-growth-says-eli-lilly-s-2-8bn-swoop-on-ataibeckley-underlines-the-value-e3431c8719546379Pharma Surgeen2026-07-17T13:17:10.000ZBiotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developershttps://www.pharmaradar360.com/article/alternative-provider-medical-services-apms-directions-043c2ff68b329a12Pharma Surgeen2026-07-17T13:13:29.000ZAlternative Provider Medical Services (APMS) Directionshttps://www.pharmaradar360.com/article/cencora-s-brent-wilhelm-on-the-inventory-paradox-behind-drug-shortages-64d4ace979f8a1c8Pharma Surgeen2026-07-17T13:09:19.000ZCencora's Brent Wilhelm on the Inventory Paradox Behind Drug Shortageshttps://www.pharmaradar360.com/article/legend-biotech-legn-could-be-60-undervalued-following-carvykti-sales-update-10cb27f4d7d248f8Pharma Surgeen2026-07-17T13:04:32.000ZLegend Biotech (LEGN) Could Be 60% Undervalued Following CARVYKTI Sales Updatehttps://www.pharmaradar360.com/article/big-pharma-just-paid-up-to-3-8-billion-for-psychedelic-medicine-and-the-rest-of-aaf9c3760f8dcd80Pharma Surgeen2026-07-17T12:50:00.000ZBig Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Timehttps://www.pharmaradar360.com/article/morning-briefing-biotech-growth-shareholders-signal-opposition-to-fund-manager-g-18e831669f7d47a8Pharma Surgeen2026-07-17T12:45:00.000ZMorning briefing: Biotech Growth shareholders signal opposition to fund manager Geoff Hsu's presence on the board; Saba lifts Gore Street Energy stake; AVI adds to Residential Secure as LIVE deal completes; plus GABIhttps://www.pharmaradar360.com/article/cybin-help-advances-psychedelic-depression-drug-to-phase-3-amid-fresh-funding-wh-a07ab8fbcb43054aPharma Surgeen2026-07-17T12:42:59.000ZCybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters?https://www.pharmaradar360.com/article/corporate-report-human-medicines-regulations-2012-advisory-bodies-annual-report-86ef90e134d27337Pharma Surgeen2026-07-17T12:30:50.000ZCorporate report: Human Medicines Regulations (2012) Advisory Bodies Annual Report 2025https://www.pharmaradar360.com/article/cue-lines-up-new-cmo-and-research-head-chutes-ladders-27a23ee414e8d6a1Pharma Surgeen2026-07-17T12:30:00.000ZCue lines up new CMO and research head—Chutes & Laddershttps://www.pharmaradar360.com/article/worldwide-healthcare-biotech-m-a-made-89-in-15-months-and-is-most-actively-manag-59792c10b2e95ce8Pharma Surgeen2026-07-17T12:17:05.000ZWorldwide Healthcare: Biotech M&A made 89% in 15 months and is "most actively managed" part of our portfoliohttps://www.pharmaradar360.com/article/veradermics-touts-oral-hair-loss-data-as-shares-jump-d63dcc8a8bee8213Pharma Surgeen2026-07-17T12:01:14.000ZVeradermics touts oral hair-loss data as shares jumphttps://www.pharmaradar360.com/article/merge-pacs-7ba5299293452363Pharma Surgeen2026-07-17T12:00:00.000ZMerge PACShttps://www.pharmaradar360.com/article/er-spec-single-use-vaginal-speculum-with-led-light-source-3c914393bef850ffPharma Surgeen2026-07-17T12:00:00.000ZER-Spec Single-Use Vaginal Speculum with LED Light Sourcehttps://www.pharmaradar360.com/article/4k-uhd-lcd-monitor-127e28651ec63facPharma Surgeen2026-07-17T12:00:00.000Z4K UHD LCD Monitorhttps://www.pharmaradar360.com/article/allergan-aesthetics-receives-approval-for-boey-trenibotulinumtoxine-for-use-in-e-8343323becc4b0d6Pharma Surgeen2026-07-17T12:00:00.000ZAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientshttps://www.pharmaradar360.com/article/amneal-expands-iohexol-injection-portfolio-with-u-s-fda-approval-of-additional-s-4bd84ad6588ffc7ePharma Surgeen2026-07-17T12:00:00.000ZAmneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentationshttps://www.pharmaradar360.com/article/using-generative-ai-to-support-revision-and-learning-40194585bf2fc528Pharma Surgeen2026-07-17T11:37:17.000ZUsing generative AI to support revision and learninghttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-un-lote-del-medicamento-veterinario-tessie-0-c4cb47d9e639f5adPharma Surgeen2026-07-17T11:35:47.000ZLa AEMPS informa de la retirada de un lote del medicamento veterinario Tessie 0,3 mg/ml solución oral para perroshttps://www.pharmaradar360.com/article/tessie-0-3-mg-ml-solucion-oral-para-perros-eu-2-21-276-001-a0744dd7af621e51Pharma Surgeen2026-07-17T11:33:54.000ZTESSIE 0,3 MG/ML SOLUCION ORAL PARA PERROS (EU/2/21/276/001)https://www.pharmaradar360.com/article/theolytics-expands-oxford-biotech-operations-with-new-facility-to-advance-theo-2-0bd655cc14212a80Pharma Surgeen2026-07-17T11:30:54.000ZTheolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapyhttps://www.pharmaradar360.com/article/who-is-tukaram-mundhe-meet-the-ias-officer-with-25-transfers-in-21-years-leading-a72aaeaf54e175c8Pharma Surgeen2026-07-17T11:02:23.000ZWho Is Tukaram Mundhe? Meet the IAS Officer With 25 Transfers In 21 Years Leading Maharashtras Food Safetyhttps://www.pharmaradar360.com/article/la-aemps-informa-sobre-el-nuevo-sistema-de-evaluacion-de-tecnologias-sanitarias-1b67643d2579238ePharma Surgeen2026-07-17T10:59:32.000ZLa AEMPS informa sobre el nuevo Sistema de Evaluación de Tecnologías Sanitarias tras la aprobación del Real Decreto 415/2026https://www.pharmaradar360.com/article/rani-links-with-pegbio-to-grow-oral-obesity-pipeline-871aae4309ac2789Pharma Surgeen2026-07-17T10:41:11.000ZRani links with PegBio to grow oral obesity pipelinehttps://www.pharmaradar360.com/article/2-reasons-to-avoid-bmrn-and-1-stock-to-buy-instead-6daa4d1c5356c13aPharma Surgeen2026-07-17T10:37:50.000Z2 Reasons to Avoid BMRN and 1 Stock to Buy Insteadhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-limited-announces-new-drug-application-for-trastuzumab-1b1895da709f0f6cPharma Surgeen2026-07-17T10:35:45.000ZCSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpahttps://www.pharmaradar360.com/article/gsk-abandons-cough-drug-added-in-2bn-bellus-deal-12ec184f2b11da15Pharma Surgeen2026-07-17T10:26:16.000ZGSK abandons cough drug added in $2bn Bellus dealhttps://www.pharmaradar360.com/article/la-aemps-informa-del-robo-y-distribucion-ilegal-de-dos-lotes-de-sensores-dexcom-b6ac66382549252aPharma Surgeen2026-07-17T10:25:04.000ZLa AEMPS informa del robo y distribución ilegal de dos lotes de sensores Dexcom G7https://www.pharmaradar360.com/article/sanofi-sues-pfizer-and-moderna-for-patent-infringements-related-to-covid-vaccine-6505ae0e0eba5dc1Pharma Surgeen2026-07-17T10:12:37.000ZSanofi sues Pfizer and Moderna for patent infringements related to COVID vaccineshttps://www.pharmaradar360.com/article/guidance-ai-airlock-sandbox-phase-2-programme-report-73318c57a9ccf366Pharma Surgeen2026-07-17T10:11:27.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/blossomhill-therapeutics-clinical-stage-oncology-biotech-files-for-nasdaq-global-06ea9eeed5096fc2Pharma Surgeen2026-07-17T10:08:00.000ZBlossomHill Therapeutics, Clinical-Stage Oncology Biotech, Files for Nasdaq Global Select Market IPOhttps://www.pharmaradar360.com/article/ph-eur-revises-general-chapter-on-alternative-microbiological-methods-49a12c52a3eedef2Pharma Surgeen2026-07-17T10:00:04.000ZPh. Eur. revises general chapter on alternative microbiological methodshttps://www.pharmaradar360.com/article/gsk-axes-key-cough-drug-candidate-after-phase-3-data-end-blockbuster-hopes-1dd70709621a8020Pharma Surgeen2026-07-17T09:46:34.000ZGSK axes key cough drug candidate after phase 3 data end blockbuster hopeshttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-nmpa-accepts-new-drug-application-for-trastuzumab-enved-b6ee04a40ea01175Pharma Surgeen2026-07-17T09:23:34.000ZCSPC Pharmaceutical Says NMPA Accepts New Drug Application For Trastuzumab Envedotin Injectionhttps://www.pharmaradar360.com/article/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in-d872850514eca694Pharma Surgeen2026-07-17T09:00:00.000ZGSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)https://www.pharmaradar360.com/article/dimerix-snaps-up-mission-s-stalled-phase-2-ready-kidney-disease-candidate-in-292-ebadbf851225c36dPharma Surgeen2026-07-17T09:00:00.000ZDimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealhttps://www.pharmaradar360.com/article/while-president-lee-jae-myung-mentioned-the-need-for-a-drug-that-induces-pregnan-f8a381ba1374c52cPharma Surgeen2026-07-17T08:56:24.000ZWhile President Lee Jae Myung mentioned the need for a drug that induces pregnancy suspension, the g..https://www.pharmaradar360.com/article/cspc-pharmaceutical-group-s-stock-price-plummets-by-6-28-dipping-to-8-06-hkd-in-416ca95ed8ff0ad1Pharma Surgeen2026-07-17T08:41:30.000ZCSPC Pharmaceutical Group's Stock Price Plummets by 6.28%, Dipping to 8.06 HKD in Recent Tradinghttps://www.pharmaradar360.com/article/the-israeli-biotech-trying-to-make-damaged-nerves-grow-again-e37e82c32c9afa45Pharma Surgeen2026-07-17T08:40:00.000ZThe Israeli biotech trying to make damaged nerves grow againhttps://www.pharmaradar360.com/article/aman-nna-republic-of-korea-donates-korean-essential-medicines-to-strengthen-heal-f958e75112a19d58Pharma Surgeen2026-07-17T08:38:42.000ZAMAN - NNA - Republic of Korea donates Korean essential medicines to strengthen health cooperation with Lebanonhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-given-consensus-rating-of-moderate-40b2074aeebf67a5Pharma Surgeen2026-07-17T08:30:58.000ZTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of "Moderate Buy" by Brokerageshttps://www.pharmaradar360.com/article/implementing-reporter-assay-based-mat-for-rapid-pyrogen-detection-bbb10d5d48332f87Pharma Surgeen2026-07-17T08:24:46.000ZImplementing reporter assay-based MAT for rapid pyrogen detectionhttps://www.pharmaradar360.com/article/alnylam-pharmaceuticals-nasdaq-alny-a-value-stock-priced-below-biotech-peers-wit-787a03631e9b3e6cPharma Surgeen2026-07-17T08:10:32.000ZAlnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growthhttps://www.pharmaradar360.com/article/qlife-targets-agreement-after-the-summer-098093059108f953Pharma Surgeen2026-07-17T07:45:50.000ZQlife targets agreement after the summerhttps://www.pharmaradar360.com/article/la-aemps-informa-del-riesgo-de-caidas-en-determinadas-gruas-winn-motion-34566e2764379ec1Pharma Surgeen2026-07-17T07:29:59.000ZLa AEMPS informa del riesgo de caídas en determinadas grúas Winn’Motionhttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-returns-to-the-spotlight-ahead-of-key-phase-f889d85265edb8b4Pharma Surgeen2026-07-17T07:17:00.000ZParadigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestonehttps://www.pharmaradar360.com/article/topiramate-market-to-reach-usd-39-6-million-by-2036-supported-by-generic-antiepi-bd63fa93f2c9986aPharma Surgeen2026-07-17T07:03:23.000ZTopiramate Market to Reach USD 39.6 Million by 2036, Supported by Generic Antiepileptic Drug Production and Regulatory Compliance | Future Market Insightshttps://www.pharmaradar360.com/article/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-52e0d33b2719579dPharma Surgeen2026-07-17T07:03:11.000ZNew autologous T cell therapy offers hope for children with brain tumorshttps://www.pharmaradar360.com/article/mumbai-s-iconic-parsi-dairy-farm-loses-license-in-maharashtra-fda-crackdown-rs-1-f4f643fe0dd5433fPharma Surgeen2026-07-17T07:02:59.000ZMumbai’s iconic Parsi Dairy Farm loses license in Maharashtra FDA crackdown; Rs 1.9 crore worth adulterated food seizedhttps://www.pharmaradar360.com/article/dimerix-expands-pipeline-with-acquisition-of-phase-2-ready-asset-for-acute-kidne-ada51482882813efPharma Surgeen2026-07-17T06:58:00.000ZDIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURYhttps://www.pharmaradar360.com/article/does-zasocitinib-s-phase-3-success-in-hard-to-treat-psoriasis-areas-change-the-b-5a415b34d16ee3adPharma Surgeen2026-07-17T06:53:52.000ZDoes Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?https://www.pharmaradar360.com/article/la-version-mise-a-jour-du-formulaire-de-demande-d-autorisation-de-mise-sur-le-ma-fc397c76f0cf22f6Pharma Surgeen2026-07-17T06:52:04.000ZLa version mise à jour du formulaire de demande d'autorisation de mise sur le marché est désormais disponible pour les procédures nationales, de reconnaissance mutuelle et décentraliséeshttps://www.pharmaradar360.com/article/annex-1-sterilisation-why-pharma-packaging-strategy-is-changing-d0874f189c71fd8bPharma Surgeen2026-07-17T06:40:43.000ZAnnex 1 sterilisation: Why pharma packaging strategy is changinghttps://www.pharmaradar360.com/article/biotech-growth-trust-portfolio-company-ataibeckley-to-be-acquired-by-eli-lilly-cf0db7612c931a38Pharma Surgeen2026-07-17T06:40:42.000ZBiotech Growth Trust Portfolio Company AtaiBeckley To Be Acquired By Eli Lillyhttps://www.pharmaradar360.com/article/biomarkers-in-nephrology-research-from-exploratory-to-decision-making-tools-2290c940259f3fc1Pharma Surgeen2026-07-17T06:40:16.000ZBiomarkers in Nephrology Research: From Exploratory to Decision-Making Toolshttps://www.pharmaradar360.com/article/us-zinc-prices-hold-steady-in-early-july-as-pharmaceutical-demand-and-supply-cos-5584fb890ab6b4dfPharma Surgeen2026-07-17T06:33:18.000ZUS Zinc Prices Hold Steady in Early July as Pharmaceutical Demand and Supply Costs Support Markethttps://www.pharmaradar360.com/article/gates-mri-serum-institute-of-india-sign-agreement-to-manufacture-tuberculosis-va-bd1656c40c414a4bPharma Surgeen2026-07-17T06:17:00.000ZGates MRI, Serum Institute of India sign agreement to manufacture Tuberculosis Vaccine candidatehttps://www.pharmaradar360.com/article/fda-accepts-resubmission-of-camurus-cam2029-nd-acf50a8147f34498Pharma Surgeen2026-07-17T05:56:16.000ZFDA accepts resubmission of Camurus' CAM2029 ND...https://www.pharmaradar360.com/article/west-wst-stock-looks-fair-on-cash-flow-yet-pricey-on-earnings-fc2502658d83384bPharma Surgeen2026-07-17T05:35:17.000ZWest (WST) Stock Looks Fair On Cash Flow Yet Pricey On Earningshttps://www.pharmaradar360.com/article/bio-asia-taiwan-2026-day-3-round-up-biotech-s-next-great-race-begins-where-disco-76d487471fd69b91Pharma Surgeen2026-07-17T05:29:29.000ZBIO Asia–Taiwan 2026 Day 3 Round-Up: Biotech’s Next Great Race Begins Where Discovery Endshttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-07-17T05:11:20.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/world-syringes-for-agilent-market-analysis-forecast-size-trends-and-insights-8e6810dd2f824fffPharma Surgeen2026-07-17T04:51:13.000ZWorld Syringes for Agilent - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/imported-seafood-mushrooms-canned-food-among-products-subject-to-increased-fda-s-be1195feaef37f74Pharma Surgeen2026-07-17T04:02:27.000ZImported seafood, mushrooms, canned food among products subject to increased FDA scrutinyhttps://www.pharmaradar360.com/article/reversing-ai-drug-discovery-belgian-biotech-sightera-raises-3m-to-learn-from-ext-b2815e249048e134Pharma Surgeen2026-07-17T04:00:34.000ZReversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology firsthttps://www.pharmaradar360.com/article/blsm-ipo-news-cancer-therapies-biotech-blossomhill-therapeutics-files-for-a-100-691f9f3cfc9614a4Pharma Surgeen2026-07-17T04:00:00.000ZBLSM IPO News - Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPOhttps://www.pharmaradar360.com/article/propylene-glycol-usp-market-forecast-points-higher-toward-2035-driven-by-pharmac-0075cc6413e5c412Pharma Surgeen2026-07-17T03:26:12.000ZPropylene Glycol USP Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Excipient Demandhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-riheart-f353dfdddfe8263dPharma Surgeen2026-07-17T03:00:00.000Z[SHINSA]English Translation of Review Report: RiHEARThttps://www.pharmaradar360.com/article/taiwan-s-biotech-ambition-gets-a-presidential-signal-as-vice-president-hsiao-bi-76d2d21c504bc23dPharma Surgeen2026-07-17T02:58:51.000ZTaiwan’s Biotech Ambition Gets a Presidential Signal as Vice President Hsiao Bi-khim Visits BIO Asia–Taiwan 2026https://www.pharmaradar360.com/article/etfs-investing-in-oneness-biotech-co-ltd-stocks-ee973db3a91d5108Pharma Surgeen2026-07-17T02:53:15.000ZETFs Investing in Oneness Biotech Co., Ltd. Stockshttps://www.pharmaradar360.com/article/top-biotech-gainers-cdna-soars-on-medicare-policy-atai-acquired-abt-lifts-outloo-42a59cac216a0496Pharma Surgeen2026-07-17T02:52:00.000ZTop Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watchhttps://www.pharmaradar360.com/article/mumbai-s-parsi-dairy-farm-food-licence-suspended-over-hygiene-and-food-safety-vi-e9433b8a521f95eaPharma Surgeen2026-07-17T02:50:00.000ZMumbai's Parsi Dairy Farm food licence suspended over hygiene and food safety violationshttps://www.pharmaradar360.com/article/mumbai-s-parsi-dairy-farm-loses-licence-after-hygiene-raids-e49aa239d719571dPharma Surgeen2026-07-17T02:40:11.000ZMumbai’s Parsi Dairy Farm Loses Licence After Hygiene Raidshttps://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82cPharma Surgeen2026-07-17T01:09:38.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/new-pharmaceutical-campus-coming-to-marion-will-further-educational-opportunitie-3830ecde5f847279Pharma Surgeen2026-07-17T01:00:00.000ZNew pharmaceutical campus coming to Marion; will further educational opportunities for ASU studentshttps://www.pharmaradar360.com/article/did-west-s-expanded-daikyo-distribution-deal-reshape-west-pharmaceutical-service-276320adf334967cPharma Surgeen2026-07-17T00:17:00.000ZDid West’s Expanded Daikyo Distribution Deal Reshape West Pharmaceutical Services' (WST) GLP‑1 Component Investment Narrative?https://www.pharmaradar360.com/article/gsk-filed-form-6-k-78ee3acd109f38b6Pharma Surgeen2026-07-17T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-38b5391da40c88ddPharma Surgeen2026-07-17T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-25b0a819f9c1458aPharma Surgeen2026-07-17T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-24bc42ce9dbe3dcdPharma Surgeen2026-07-17T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-12c700d155bac7cdPharma Surgeen2026-07-17T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-eb5783e0703af792Pharma Surgeen2026-07-17T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-fe40761adb6748c1Pharma Surgeen2026-07-17T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-45cf4dd599048091Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-d060d0f83b1662f9Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a051ca4aa25c93a4Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e83c942f88b483e0Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-df9581853f129271Pharma Surgeen2026-07-17T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fc125ae779d863f6Pharma Surgeen2026-07-17T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-60836779eb0d2615Pharma Surgeen2026-07-17T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b8ed3598d7259c02Pharma Surgeen2026-07-17T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6059ec1a65c791f5Pharma Surgeen2026-07-17T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-22a9ea239a8aef47Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: National Practitioner Data Bank for Adverse Information on Physicians and Other Health Care Practitioners-45 CFR Part 60 Regulations and Forms, OMB No. 0906-0081-Revisionhttps://www.pharmaradar360.com/article/national-center-for-complementary-integrative-health-notice-of-meeting-78ddeab291738ed7Pharma Surgeen2026-07-17T00:00:00.000ZNational Center for Complementary & Integrative Health; Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-acc-65561b53e7bd35dbPharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Programhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-adv-86860004be8ccac1Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Adverse Event Program for Medical Devices: (Medical Product Safety Network (MedSun))https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-inf-0fd07d7bbe69b004Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirementshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-03b98120c4322232Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Voluntary Improvement Programhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-vol-192486c6c11b21a3Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Voluntary National Retail Food Regulatory Program Standardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-req-0a6dbf37b076ebadPharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Cosmetic Productshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-714edd0b9db5bb65Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/doctor-urges-caution-with-electric-bikes-and-scooters-33805eff94dbfdbcPharma Surgeen2026-07-17T00:00:00.000ZDoctor Urges Caution with Electric Bikes and Scootershttps://www.pharmaradar360.com/article/drug-trials-snapshots-zycubo-92a27a298e96a33fPharma Surgeen2026-07-17T00:00:00.000ZDrug Trials Snapshots: ZYCUBOhttps://www.pharmaradar360.com/article/clinical-epidemiological-and-spatial-profile-by-degree-of-physical-disability-in-097013f76f5332a9Pharma Surgeen2026-07-17T00:00:00.000ZClinical-Epidemiological and Spatial Profile by Degree of Physical Disability in Leprosy in the State of Pará, Brazilian Amazon (2013 to 2024): A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/clinical-readiness-of-nursing-students-in-oman-a-sequential-explanatory-mixed-me-dbaa8f8d3d893c9ePharma Surgeen2026-07-17T00:00:00.000ZClinical Readiness of Nursing Students in Oman: A Sequential Explanatory Mixed-Methods Studyhttps://www.pharmaradar360.com/article/therapeutic-exercise-in-the-management-of-sarcopenia-a-narrative-review-of-curre-c74d997c61157d80Pharma Surgeen2026-07-17T00:00:00.000ZTherapeutic Exercise in the Management of Sarcopenia: A Narrative Review of Current Evidence and Clinical Implicationshttps://www.pharmaradar360.com/article/comparative-dpph-radical-scavenging-activity-phytochemical-profiling-ft-ir-analy-a8a42663f63d414aPharma Surgeen2026-07-17T00:00:00.000ZComparative DPPH Radical Scavenging Activity, Phytochemical Profiling, FT-IR Analysis, and In-silico Molecular Docking Studies of Sap (Latex) from Jatropha Specieshttps://www.pharmaradar360.com/article/antifungal-sesquiterpens-8-epi-xanthatin-and-8-epixanthatin-1-5-epoxide-isolated-42fa445e0282c54ePharma Surgeen2026-07-17T00:00:00.000ZANTIFUNGAL SESQUITERPENS 8-EPI-XANTHATIN AND 8-EPIXANTHATIN-1, 5-EPOXIDE ISOLATED FROM LEAVES OF XANTHIUM STRUMARIUMhttps://www.pharmaradar360.com/article/clinical-determinants-of-in-hospital-mortality-in-a-multicenter-coronary-care-un-b8486483958786c9Pharma Surgeen2026-07-17T00:00:00.000ZClinical Determinants of In-Hospital Mortality in a Multicenter Coronary Care Unit Cohorthttps://www.pharmaradar360.com/article/effects-of-functional-training-on-body-composition-in-adults-with-overweight-or-08abf5a0ced8a64ePharma Surgeen2026-07-17T00:00:00.000ZEffects of Functional Training on Body Composition in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Clinical Trialshttps://www.pharmaradar360.com/article/abdominal-wall-endometriosis-following-cesarean-section-a-retrospective-analysis-f7cf77cab5530c41Pharma Surgeen2026-07-17T00:00:00.000ZAbdominal Wall Endometriosis Following Cesarean Section: A Retrospective Analysishttps://www.pharmaradar360.com/article/computed-tomography-based-comparison-of-anterior-and-posterior-cortical-thicknes-cfd79f332a20fa7ePharma Surgeen2026-07-17T00:00:00.000ZComputed Tomography-Based Comparison of Anterior and Posterior Cortical Thickness Around the Interfragmentary Screw Fixation Level in Weber B Lateral Malleolar Fractureshttps://www.pharmaradar360.com/article/a-20-year-spatio-temporal-analysis-of-gender-workforce-in-medical-departments-of-247280618ba58cb6Pharma Surgeen2026-07-17T00:00:00.000ZA 20-Year Spatio-Temporal Analysis of Gender Workforce in Medical Departments of Psychiatry/Psychotherapy and Neurology in Germanyhttps://www.pharmaradar360.com/article/first-trimester-maternal-serum-growth-arrest-specific-protein-6-gas6-levels-for-d7e1f68a2687d1cfPharma Surgeen2026-07-17T00:00:00.000ZFirst-Trimester Maternal Serum Growth Arrest-Specific Protein 6 (Gas6) Levels for the Prediction of Preeclampsiahttps://www.pharmaradar360.com/article/lower-urinary-tract-symptoms-in-women-with-surgically-confirmed-endometriosis-as-29063b9ca564b58fPharma Surgeen2026-07-17T00:00:00.000ZLower Urinary Tract Symptoms in Women with Surgically Confirmed Endometriosis: Association with Urethral Ultrasonographic Findingshttps://www.pharmaradar360.com/article/sex-specific-association-between-serum-sod-activity-and-osteoporosis-in-type-2-d-9ec49788551ea6b9Pharma Surgeen2026-07-17T00:00:00.000ZSex-Specific Association Between Serum SOD Activity and Osteoporosis in Type 2 Diabetes: A Cross-Sectional Study with Functional Validationhttps://www.pharmaradar360.com/article/uncovering-patient-reported-and-observed-barriers-and-facilitators-to-sufficient-cb66070bb67040a8Pharma Surgeen2026-07-17T00:00:00.000ZUncovering Patient-Reported and Observed Barriers and Facilitators to Sufficient Dietary Intake in Acutely Admitted Older Adults: Insights from a Nutritional Trialhttps://www.pharmaradar360.com/article/crispr-cas9-in-cancer-therapy-clinical-translation-mechanistic-strategies-and-th-9f8f4551cae9383aPharma Surgeen2026-07-17T00:00:00.000ZCRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directionshttps://www.pharmaradar360.com/article/lactiplantibacillus-plantarum-probio87-supplementation-improves-functional-const-8e1954196f1a4df5Pharma Surgeen2026-07-17T00:00:00.000ZLactiplantibacillus plantarum Probio87 supplementation improves functional constipation and is associated with peripheral gene-expression responses related to inflammation and the gut–brain axis: a randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/effects-of-ketogenic-diet-therapy-in-outpatient-anti-epileptic-drug-cost-reducti-f7ecd5e8720baae8Pharma Surgeen2026-07-17T00:00:00.000ZEffects of ketogenic diet therapy in outpatient anti epileptic drug cost reduction and parental satisfaction among children with intractable epilepsyhttps://www.pharmaradar360.com/article/conceptualizing-and-treating-the-polytrauma-clinical-triad-as-a-complex-chronic-8ba03be5e6d80a6cPharma Surgeen2026-07-17T00:00:00.000ZConceptualizing and treating the polytrauma clinical triad as a complex chronic pain syndromehttps://www.pharmaradar360.com/article/vedolizumab-in-biologic-naive-ulcerative-colitis-a-multicenter-real-world-evalua-a04324aaad4c84dePharma Surgeen2026-07-17T00:00:00.000ZVedolizumab in biologic-naïve ulcerative colitis: a multicenter real-world evaluation of clinical benefits and exploratory inflammatory indiceshttps://www.pharmaradar360.com/article/toward-explainable-and-adaptive-artificial-intelligence-systems-for-antimicrobia-1bd80ca6b41e2c8bPharma Surgeen2026-07-17T00:00:00.000ZToward explainable and adaptive artificial intelligence systems for antimicrobial peptide discovery under resistance pressurehttps://www.pharmaradar360.com/article/efficacy-and-safety-of-acupuncture-for-coronary-microvascular-disease-study-prot-e539a194a71fd820Pharma Surgeen2026-07-17T00:00:00.000ZEfficacy and safety of acupuncture for coronary microvascular disease: study protocol for a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/twenty-years-of-frontal-lobe-surgery-clinical-outcomes-and-lessons-from-the-fron-e2b5843edf2151cePharma Surgeen2026-07-17T00:00:00.000ZTwenty years of frontal lobe surgery: Clinical outcomes and lessons from the frontierhttps://www.pharmaradar360.com/article/design-synthesis-and-in-vitro-evaluation-of-novel-propellanebased-alkaloid-analo-4934f1749d33ba8cPharma Surgeen2026-07-17T00:00:00.000ZDesign, Synthesis and In Vitro Evaluation of Novel PropellaneBased Alkaloid Analogueshttps://www.pharmaradar360.com/article/scleromyxedema-as-a-manifestation-of-monoclonal-gammapathy-of-clinical-significa-8e22b7a7c3dc6033Pharma Surgeen2026-07-17T00:00:00.000ZScleromyxedema as a manifestation of monoclonal gammapathy of clinical significancehttps://www.pharmaradar360.com/article/clinical-and-microbiological-profile-of-neonates-admitted-in-nicu-and-its-short-b4206c65ebde53a1Pharma Surgeen2026-07-17T00:00:00.000ZClinical and Microbiological Profile of Neonates Admitted in Nicu and its Short-Term Outcomehttps://www.pharmaradar360.com/article/temperature-excursion-risk-window-in-pharmaceutical-air-cargo-b4268d10e91edc9aPharma Surgeen2026-07-17T00:00:00.000ZTemperature Excursion Risk Window in Pharmaceutical Air Cargohttps://www.pharmaradar360.com/article/directory-of-open-access-journals-indexing-and-new-clinical-perspectives-in-the-0e507ec78d488e88Pharma Surgeen2026-07-17T00:00:00.000ZDirectory of Open Access Journals indexing and new clinical perspectives in the second issue of 2026https://www.pharmaradar360.com/article/clinical-hemato-biochemical-and-ultrasonographic-alterations-in-dogs-with-pancre-82db0f42fc26820cPharma Surgeen2026-07-17T00:00:00.000ZClinical, Hemato-biochemical and Ultrasonographic Alterations in Dogs with Pancreatitis and their Therapeutic Managementhttps://www.pharmaradar360.com/article/identifying-tmem127-deficient-pheochromocytomas-paragangliomas-via-ret-overexpre-54d50ed3a0953ff6Pharma Surgeen2026-07-17T00:00:00.000ZIdentifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistryhttps://www.pharmaradar360.com/article/symptom-oriented-clinical-psychiatry-495e10271aa81ebcPharma Surgeen2026-07-17T00:00:00.000ZSymptom-oriented clinical psychiatryhttps://www.pharmaradar360.com/article/cancer-stem-cells-and-drug-resistance-in-cancer-molecular-mechanisms-and-therape-2c972c34aa8af6fbPharma Surgeen2026-07-17T00:00:00.000ZCancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targetshttps://www.pharmaradar360.com/article/tracheal-rhinoscleroma-clinical-endoscopic-and-radiological-features-in-a-five-p-b2a52ed6ebb4943ePharma Surgeen2026-07-17T00:00:00.000ZTracheal rhinoscleroma: clinical, endoscopic, and radiological features in a five-patient case series and literature reviewhttps://www.pharmaradar360.com/article/nigerian-medicinal-plants-on-the-road-to-drug-discovery-prospects-and-challenges-0c46b46f0856bd60Pharma Surgeen2026-07-17T00:00:00.000ZNigerian medicinal plants on the road to drug discovery: prospects and challengeshttps://www.pharmaradar360.com/article/do-subsidies-reach-the-sick-implementation-challenges-and-equity-implications-of-54bcab88fe6b2003Pharma Surgeen2026-07-17T00:00:00.000ZDo subsidies reach the sick? Implementation challenges and equity implications of pharmaceutical subsidy reform in Iran: a qualitative studyhttps://www.pharmaradar360.com/article/work-life-spillover-clinical-decision-making-and-quality-of-care-in-nursing-the-ba562ba90776487bPharma Surgeen2026-07-17T00:00:00.000ZWork-life spillover, clinical decision-making, and quality of care in nursing: the role of negative interferencehttps://www.pharmaradar360.com/article/cbl-with-integrated-sdh-versus-cbl-alone-in-esophageal-surgery-internship-a-rand-a34930a1b70e6705Pharma Surgeen2026-07-17T00:00:00.000ZCBL with integrated SDH versus CBL alone in esophageal surgery internship: a randomized controlled trial on clinical competence developmenthttps://www.pharmaradar360.com/article/effect-of-framed-mhealth-messages-on-oral-hygiene-and-quality-of-life-among-suda-a09b120c67efc234Pharma Surgeen2026-07-17T00:00:00.000ZEffect of framed mHealth messages on oral hygiene and quality of life among Sudanese refugees in Egypt: a randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-associated-factors-of-post-infectious-bronchiolitis-f4ca7d53dd6c0e07Pharma Surgeen2026-07-17T00:00:00.000ZClinical characteristics and associated factors of post-infectious bronchiolitis obliterans in children with severe pneumonia and respiratory failure: a retrospective cohort studyhttps://www.pharmaradar360.com/article/study-protocol-of-the-c-solve-jaccro-gc-12-trial-a-randomized-non-comparative-ph-dd64102ee172172aPharma Surgeen2026-07-17T00:00:00.000ZStudy protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancerhttps://www.pharmaradar360.com/article/syne1-related-motor-neuron-disease-like-phenotype-with-mild-distal-contractures-f41be1eb2d2cafc1Pharma Surgeen2026-07-17T00:00:00.000ZSYNE1-Related motor neuron disease-like phenotype with mild distal contractures and 24-month clinical stability: a case reporthttps://www.pharmaradar360.com/article/clinical-characteristics-associated-with-severe-misdiagnosis-of-scabies-a-retros-8caa8a0959e6019aPharma Surgeen2026-07-17T00:00:00.000ZClinical characteristics associated with severe misdiagnosis of scabies: a retrospective hospital-based studyhttps://www.pharmaradar360.com/article/clinical-value-of-rt-3de-in-evaluating-mitral-valve-configuration-and-the-occurr-47b6e06f32ea36bePharma Surgeen2026-07-17T00:00:00.000ZClinical value of RT-3DE in evaluating mitral valve configuration and the occurrence of VFMR in patients with ischemic cardiomyopathy: a clinical investigationhttps://www.pharmaradar360.com/article/observation-on-clinical-efficacy-and-safety-of-acupuncture-combined-with-lefluno-5b228054d28c0e23Pharma Surgeen2026-07-17T00:00:00.000ZObservation on Clinical Efficacy and Safety of Acupuncture Combined With Leflunomide in the Treatment of Rheumatoid Arthritishttps://www.pharmaradar360.com/article/tumor-infiltrating-lymphocytes-as-a-predictor-of-adjuvant-avelumab-efficacy-in-p-7611b8b36f14c9a3Pharma Surgeen2026-07-17T00:00:00.000ZTumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancerhttps://www.pharmaradar360.com/article/supplementary-figure-s1-from-preclinical-activity-of-the-b7-h3-targeting-antibod-d01ba96a7a89aa34Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-figure-s3-from-preclinical-activity-of-the-b7-h3-targeting-antibod-3c53ae3831eb604aPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S3 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s10-from-preclinical-activity-of-the-b7-h3-targeting-antibod-18e91b8ad1d7ea8dPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s11-from-preclinical-activity-of-the-b7-h3-targeting-antibod-d6af67ba4162416dPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S11 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s4-from-preclinical-activity-of-the-b7-h3-targeting-antibody-01e5fd5281bbf6d0Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S4 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s7-from-preclinical-activity-of-the-b7-h3-targeting-antibody-01f7c0cc76953af5Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-figure-s2-from-gemcitabine-plus-nivolumab-with-carboplatin-or-oxal-349a281fe0c01620Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S2 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/supplementary-figure-s5-from-gemcitabine-plus-nivolumab-with-carboplatin-or-oxal-470d51ed21ae7eafPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S5 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/supplementary-figure-s3-from-a-single-arm-phase-2-trial-of-doxorubicin-plus-zali-685e572884435db9Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S3 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomashttps://www.pharmaradar360.com/article/scarlett-mcnally-clinical-audit-needs-a-shake-up-588df5a0ce5ba9efPharma Surgeen2026-07-17T00:00:00.000ZScarlett McNally: Clinical audit needs a shake-uphttps://www.pharmaradar360.com/article/partner-a-toolbox-for-patient-and-public-involvement-governance-within-health-pr-654f7daed3ad5af9Pharma Surgeen2026-07-17T00:00:00.000ZPARTNER: A Toolbox for Patient and Public Involvement Governance Within Health Professions Education Researchhttps://www.pharmaradar360.com/article/artistic-realism-or-clinical-evidence-periodontitis-and-pathological-tooth-migra-4ddc1413c07d87b2Pharma Surgeen2026-07-17T00:00:00.000ZArtistic Realism or Clinical Evidence? Periodontitis and Pathological Tooth Migration in Caravaggio's Goliath and Medusahttps://www.pharmaradar360.com/article/epidemiology-of-children-and-young-people-presenting-to-australian-emergency-dep-5820d0d15b86357dPharma Surgeen2026-07-17T00:00:00.000ZEpidemiology of Children and Young People Presenting to Australian Emergency Departments for the Management of Acute Severe Behavioural Disturbance: Secondary Analysis of a Randomised Controlled Trialhttps://www.pharmaradar360.com/article/withania-somnifera-ashwagandha-as-an-adjunctive-treatment-to-antipsychotic-medic-60d72841f477cfc7Pharma Surgeen2026-07-17T00:00:00.000ZWithania somnifera (Ashwagandha) as an Adjunctive Treatment to Antipsychotic Medications for Patients With Schizophreniahttps://www.pharmaradar360.com/article/pemphigoid-was-not-associated-with-increased-risk-of-solid-organ-hematologic-or-e5757299f4a78a55Pharma Surgeen2026-07-17T00:00:00.000ZPemphigoid was not associated with increased risk of solid organ, hematologic, or nonmelanoma skin malignancies in a nationally representative matched cohorthttps://www.pharmaradar360.com/article/an-innovative-injection-technique-for-treating-edematous-fibrosclerotic-pannicul-d41234fd6f83921fPharma Surgeen2026-07-17T00:00:00.000ZAn Innovative Injection Technique for Treating Edematous Fibrosclerotic Panniculopathy (Cellulite): A Prospective Multicenter Clinical Investigationhttps://www.pharmaradar360.com/article/rotation-traction-manipulation-versus-cervical-traction-for-axial-neck-pain-caus-5c5f071792595a89Pharma Surgeen2026-07-17T00:00:00.000ZRotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/psychiatric-and-medical-comorbidities-in-patients-with-migraine-before-and-durin-81f8a6a37a44c141Pharma Surgeen2026-07-17T00:00:00.000ZPsychiatric and medical comorbidities in patients with migraine before and during the COVID-19 pandemic in Thailand: a retrospective comparative cohort study of two different clinical groupshttps://www.pharmaradar360.com/article/suprachoroidal-hemorrhage-after-anterior-segment-surgery-clinical-features-and-m-d59747c7f1c8ab74Pharma Surgeen2026-07-17T00:00:00.000ZSuprachoroidal hemorrhage after anterior segment surgery: clinical features and management outcomeshttps://www.pharmaradar360.com/article/advances-in-antibody-drug-conjugate-based-combination-therapy-strategies-for-non-56e4f641a82a584dPharma Surgeen2026-07-17T00:00:00.000ZAdvances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancerhttps://www.pharmaradar360.com/article/clinical-characteristics-treatment-and-prognosis-of-ixekizumab-induced-inflammat-8dd41184c8042812Pharma Surgeen2026-07-17T00:00:00.000ZClinical characteristics, treatment, and prognosis of ixekizumab-induced inflammatory bowel diseasehttps://www.pharmaradar360.com/article/innovative-applications-of-microbial-carotenoids-in-the-pharmaceutical-cosmetic-9221229cad02ee93Pharma Surgeen2026-07-17T00:00:00.000ZInnovative Applications of Microbial Carotenoids in the Pharmaceutical, Cosmetic, and Nutraceutical Sectorshttps://www.pharmaradar360.com/article/adopting-the-lancet-commission-definition-of-clinical-obesity-in-metabolic-dysfu-3530923835496922Pharma Surgeen2026-07-17T00:00:00.000ZAdopting the lancet commission definition of clinical obesity in metabolic dysfunction-associated steatotic liver disease (MASLD)https://www.pharmaradar360.com/article/drug-doses-converge-while-environmental-and-occupational-thresholds-diverge-a-bi-c6d1c790eb3a8fa9Pharma Surgeen2026-07-17T00:00:00.000ZDrug Doses Converge while Environmental and Occupational Thresholds Diverge: A Biological Paradoxhttps://www.pharmaradar360.com/article/isolated-congenital-eyelid-eversion-with-familial-occurrence-a-rare-clinical-ent-1a4dd61f637b8164Pharma Surgeen2026-07-17T00:00:00.000ZIsolated congenital eyelid eversion with familial occurrence: a rare clinical entityhttps://www.pharmaradar360.com/article/symptomatic-intracranial-hemorrhage-and-other-complications-with-tenecteplase-ve-b0a46f2a4abd6c84Pharma Surgeen2026-07-17T00:00:00.000ZSymptomatic Intracranial Hemorrhage and Other Complications with Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysishttps://www.pharmaradar360.com/article/empagliflozin-in-stemi-patients-a-randomized-controlled-trial-on-left-ventricula-7ffff66bfd513e92Pharma Surgeen2026-07-17T00:00:00.000ZEmpagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomeshttps://www.pharmaradar360.com/article/a-rare-case-of-a-ciliated-hepatic-foregut-cyst-with-progressive-enlargement-caus-e7ee20f3bc230ef7Pharma Surgeen2026-07-17T00:00:00.000ZA rare case of a ciliated hepatic foregut cyst with progressive enlargement causing obstructive jaundicehttps://www.pharmaradar360.com/article/not-all-screen-use-is-equal-shifting-the-focus-from-screen-time-to-problematic-u-21fa76a223966971Pharma Surgeen2026-07-17T00:00:00.000ZNot All Screen Use is Equal: Shifting the Focus from Screen Time to Problematic Use in Child and Adolescent Well-Being Researchhttps://www.pharmaradar360.com/article/hiv-related-stigma-in-people-living-with-hiv-a-cross-sectional-analysis-of-a-por-7e00a38da7626e24Pharma Surgeen2026-07-17T00:00:00.000ZHIV-Related Stigma in People Living with HIV: A Cross-Sectional Analysis of a Portuguese Clinical Cohorthttps://www.pharmaradar360.com/article/dietary-fatty-acids-intake-and-the-risk-of-advanced-cardiovascular-kidney-metabo-a241b60d2efa6517Pharma Surgeen2026-07-17T00:00:00.000ZDietary fatty acids intake and the risk of advanced cardiovascular-kidney-metabolic syndrome: evidence from NHANES 1999–2018https://www.pharmaradar360.com/article/does-alternate-day-bathing-with-2-chlorhexidine-improve-clinical-outcomes-in-cri-1e518984ec1ab4e2Pharma Surgeen2026-07-17T00:00:00.000ZDoes alternate-day bathing with 2% chlorhexidine improve clinical outcomes in critically ill patients? A systematic review and meta-analysishttps://www.pharmaradar360.com/article/is-a-doctor-still-a-doctor-if-he-s-not-doctoring-reflections-on-a-life-of-doctor-e2bb8d17f6ff720cPharma Surgeen2026-07-17T00:00:00.000ZIs a doctor still a doctor if he’s not doctoring? Reflections on a life of doctoringhttps://www.pharmaradar360.com/article/diagnostic-accuracy-of-qraypen-fluorescence-scoring-for-secondary-caries-in-repa-3448708ddae03468Pharma Surgeen2026-07-17T00:00:00.000ZDiagnostic accuracy of QrayPen fluorescence scoring for secondary caries in repair-/replacement-indicated posterior composite restorationshttps://www.pharmaradar360.com/article/the-human-trophoblast-cell-surface-antigen-2-trop-2-expression-on-metastasized-b-ff723a5737303765Pharma Surgeen2026-07-17T00:00:00.000ZThe human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancerhttps://www.pharmaradar360.com/article/retinal-ischemic-perivascular-lesions-in-patients-with-pulmonary-embolism-an-oct-a694e2f5b0d10e66Pharma Surgeen2026-07-17T00:00:00.000ZRetinal ischemic perivascular lesions in patients with pulmonary embolism: an OCT angiography studyhttps://www.pharmaradar360.com/article/sub-tenon-s-triamcinolone-bridging-to-adalimumab-therapy-in-refractory-noninfect-cab78a50d0c7274fPharma Surgeen2026-07-17T00:00:00.000ZSub-Tenon’s triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edemahttps://www.pharmaradar360.com/article/chessboard-microneedle-array-for-inflammation-regulation-via-spatiotemporally-co-5c76f3aafb0f2ecfPharma Surgeen2026-07-17T00:00:00.000ZChessboard Microneedle Array for Inflammation Regulation via Spatiotemporally Controlled Drug Deliveryhttps://www.pharmaradar360.com/article/nct07712770-pilot-radioembolisation-clinical-trial-assessing-safety-and-efficacy-9d87fa0694fea15bPharma Surgeen2026-07-17T00:00:00.000ZNCT07712770: Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Gliomahttps://www.pharmaradar360.com/article/nct07712536-phase-iia-study-of-pharmacokinetics-safety-and-efficacy-of-qy201-tab-2821a851f39fef51Pharma Surgeen2026-07-17T00:00:00.000ZNCT07712536: Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitishttps://www.pharmaradar360.com/article/nct07712198-al-prediction-of-sarcopenia-risk-in-neurocritical-icu-patients-a886b04538f6da1cPharma Surgeen2026-07-17T00:00:00.000ZNCT07712198: Al Prediction of Sarcopenia Risk in Neurocritical ICU Patientshttps://www.pharmaradar360.com/article/nct07712068-effects-of-exercise-sequence-and-meal-sequence-on-weight-management-8832646a9c569c6dPharma Surgeen2026-07-17T00:00:00.000ZNCT07712068: Effects of Exercise Sequence and Meal Sequence on Weight Management Among Children and Adolescents With Overweight or Obesity: The STEP Trialhttps://www.pharmaradar360.com/article/nct07711977-efficacy-of-acupuncture-for-postoperative-urinary-retention-followin-b8e0c3328047bea6Pharma Surgeen2026-07-17T00:00:00.000ZNCT07711977: Efficacy of Acupuncture for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancerhttps://www.pharmaradar360.com/article/nct07711769-nurse-led-digital-cognitive-behavioral-therapy-for-insomnia-dcbt-i-i-126780c55570d9bePharma Surgeen2026-07-17T00:00:00.000ZNCT07711769: Nurse-led Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) in University Students With Mild to Moderate Mental Health Problemshttps://www.pharmaradar360.com/article/nct07711717-i-can-uganda-effectiveness-trial-54edcce6cd32356ePharma Surgeen2026-07-17T00:00:00.000ZNCT07711717: I-CAN Uganda Effectiveness Trialhttps://www.pharmaradar360.com/article/nct07711210-efficacy-and-safety-of-the-acc017-based-antiretroviral-regimen-in-tr-b89ee093f7e17145Pharma Surgeen2026-07-17T00:00:00.000ZNCT07711210: Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutationshttps://www.pharmaradar360.com/article/nct07710872-immunogenicity-and-safety-study-of-an-investigational-quadrivalent-m-327ac00e0427d89dPharma Surgeen2026-07-17T00:00:00.000ZNCT07710872: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in Chinahttps://www.pharmaradar360.com/article/nct07710638-efficacy-of-ivermectin-in-the-treatment-of-plane-warts-bb130e341574537bPharma Surgeen2026-07-17T00:00:00.000ZNCT07710638: Efficacy of Ivermectin in the Treatment of Plane Wartshttps://www.pharmaradar360.com/article/nct07710157-a-randomized-controlled-two-arm-1-1-ratio-phase-iia-trial-to-assess-4e8c421adffd59e0Pharma Surgeen2026-07-17T00:00:00.000ZNCT07710157: A Randomized Controlled, Two-arm (1:1 Ratio) Phase IIa Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With de Novo Minimal Change Diseasehttps://www.pharmaradar360.com/article/nct07710066-analysis-of-weaning-of-analgosedation-and-kinetics-of-emergence-in-c-40c361f6d1037d3fPharma Surgeen2026-07-17T00:00:00.000ZNCT07710066: Analysis of Weaning of Analgosedation and Kinetics of Emergence in Critically Ill Patientshttps://www.pharmaradar360.com/article/nct07704333-assessment-of-18f-fluorocellobiose-18f-fcb-pharmacokinetics-in-healt-6f11aca8d1728919Pharma Surgeen2026-07-17T00:00:00.000ZNCT07704333: Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infectionshttps://www.pharmaradar360.com/article/nct07703709-colorectal-cancer-real-world-outcomes-study-of-survival-with-immunom-5e8350d2883ca063Pharma Surgeen2026-07-17T00:00:00.000ZNCT07703709: Colorectal Cancer Real-world Outcomes Study of Survival With Immunomodulator Plus Standard Anti-cancer Therapieshttps://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00Pharma Surgeen2026-07-17T00:00:00.000ZNCT07686380: IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapyhttps://www.pharmaradar360.com/article/nct07505771-a-phase-1-study-of-177lu-im-3050-in-participants-with-advanced-cance-453aca112d1f2d82Pharma Surgeen2026-07-17T00:00:00.000ZNCT07505771: A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancerhttps://www.pharmaradar360.com/article/nct07287098-a-study-of-imlunestrant-ly3484356-in-premenopausal-women-with-estrog-b23919f7a99faf35Pharma Surgeen2026-07-17T00:00:00.000ZNCT07287098: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancerhttps://www.pharmaradar360.com/article/nct07226843-a-study-of-ly4584180-in-adult-participants-with-previously-treated-b-b4fe8c2e70e70af3Pharma Surgeen2026-07-17T00:00:00.000ZNCT07226843: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancershttps://www.pharmaradar360.com/article/nct07222488-a-clinical-study-of-mk-3120-in-people-with-bladder-cancer-mk-3120-00-af453328dc057ea1Pharma Surgeen2026-07-17T00:00:00.000ZNCT07222488: A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)https://www.pharmaradar360.com/article/nct07165028-a-master-protocol-of-multiple-agents-in-adults-with-metabolic-dysfun-6c7249a8247ece59Pharma Surgeen2026-07-17T00:00:00.000ZNCT07165028: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)https://www.pharmaradar360.com/article/nct07064018-trial-of-single-protein-encapsulated-doxorubicin-spedox-6-in-advance-bbf2e6f3dedf6007Pharma Surgeen2026-07-17T00:00:00.000ZNCT07064018: Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancieshttps://www.pharmaradar360.com/article/nct06948110-deciphering-the-genetic-architecture-of-autoimmune-diseases-353665cab37b522aPharma Surgeen2026-07-17T00:00:00.000ZNCT06948110: Deciphering the Genetic Architecture of Autoimmune Diseaseshttps://www.pharmaradar360.com/article/nct06615973-screening-for-social-determinants-of-health-sdoh-and-cognitive-funct-69af5e89852e6a1aPharma Surgeen2026-07-17T00:00:00.000ZNCT06615973: Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Strokehttps://www.pharmaradar360.com/article/nct06581146-a-study-to-check-liver-health-in-boys-with-xlmtm-a-serious-genetic-m-335b3e3adde503c2Pharma Surgeen2026-07-17T00:00:00.000ZNCT06581146: A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Conditionhttps://www.pharmaradar360.com/article/nct06565689-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pre-e83ecda77cfb23fbPharma Surgeen2026-07-17T00:00:00.000ZNCT06565689: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012https://www.pharmaradar360.com/article/nct06513962-triptorelin-for-the-prevention-of-ovarian-damage-in-adolescents-and-b4ab2fdd0953c335Pharma Surgeen2026-07-17T00:00:00.000ZNCT06513962: Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancerhttps://www.pharmaradar360.com/article/nct06406465-a-ugt1a1-genotype-directed-study-of-belinostat-pharmacokinetics-and-bec826a8d1d0b74cPharma Surgeen2026-07-17T00:00:00.000ZNCT06406465: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicityhttps://www.pharmaradar360.com/article/nct06398444-a-clinical-study-of-lutetium-177lu-oxodotreotide-injection-in-patien-c1dd017909d2e845Pharma Surgeen2026-07-17T00:00:00.000ZNCT06398444: A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasmshttps://www.pharmaradar360.com/article/nct06370728-a-drug-drug-interaction-ddi-study-of-orforglipron-with-carbamazepine-5bd69cadc74d35ddPharma Surgeen2026-07-17T00:00:00.000ZNCT06370728: A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participantshttps://www.pharmaradar360.com/article/nct06251310-sw-682-in-advanced-solid-tumors-64b8a0d9fa88e711Pharma Surgeen2026-07-17T00:00:00.000ZNCT06251310: SW-682 in Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05971758-fimepinostat-combination-hdac-and-pi3-kinase-inhibitor-tumor-directe-346fbee998f7d7aePharma Surgeen2026-07-17T00:00:00.000ZNCT05971758: Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Diseasehttps://www.pharmaradar360.com/article/nct05835310-an-efficacy-and-safety-study-of-intravenous-anifrolumab-to-treat-sys-8efc85c09de4a068Pharma Surgeen2026-07-17T00:00:00.000ZNCT05835310: An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participantshttps://www.pharmaradar360.com/article/nct05827081-phase-iiib-study-of-ribociclib-et-in-early-breast-cancer-af4028810169a04cPharma Surgeen2026-07-17T00:00:00.000ZNCT05827081: Phase IIIb Study of Ribociclib + ET in Early Breast Cancerhttps://www.pharmaradar360.com/article/nct05706311-community-pharmacy-based-prescription-drug-monitoring-program-opioid-7499fe31a83124fePharma Surgeen2026-07-17T00:00:00.000ZNCT05706311: Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Toolhttps://www.pharmaradar360.com/article/nct05429632-mocravimod-as-adjunctive-and-maintenance-treatment-in-aml-patients-u-c26b21791eddbd2dPharma Surgeen2026-07-17T00:00:00.000ZNCT05429632: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCThttps://www.pharmaradar360.com/article/nct05108298-improving-adolescent-and-young-adult-self-reported-data-in-ecog-acri-d382ecc7d8c5bb3bPharma Surgeen2026-07-17T00:00:00.000ZNCT05108298: Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trialshttps://www.pharmaradar360.com/article/nct05010018-a-mobile-application-to-improve-procurement-and-distribution-of-heal-d02485a36c1d99eePharma Surgeen2026-07-17T00:00:00.000ZNCT05010018: A Mobile Application to Improve Procurement and Distribution of Healthful Foods & Beverages in Baltimore Cityhttps://www.pharmaradar360.com/article/nct04395079-brachytherapy-with-durvalumab-or-tremelimumab-for-the-treatment-of-p-ba669e2b2c28221dPharma Surgeen2026-07-17T00:00:00.000ZNCT04395079: Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancieshttps://www.pharmaradar360.com/article/nct03827941-auricular-transcutaneous-electrical-nerve-stimulation-treatment-of-a-39e2435d1a4729edPharma Surgeen2026-07-17T00:00:00.000ZNCT03827941: Auricular Transcutaneous Electrical Nerve Stimulation Treatment of Autismhttps://www.pharmaradar360.com/article/nct03804255-assessment-of-current-biomarker-testing-practices-for-common-solid-c-5619d52c79fb59f7Pharma Surgeen2026-07-17T00:00:00.000ZNCT03804255: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Settinghttps://www.pharmaradar360.com/article/nct03648905-clinical-laboratory-evaluation-of-chronic-autonomic-failure-2db42817027cd55dPharma Surgeen2026-07-17T00:00:00.000ZNCT03648905: Clinical Laboratory Evaluation of Chronic Autonomic Failurehttps://www.pharmaradar360.com/article/nct02484404-phase-i-ii-study-of-the-anti-programmed-death-ligand-1-durvalumab-an-eb6da2bc9f88415fPharma Surgeen2026-07-17T00:00:00.000ZNCT02484404: Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...https://www.pharmaradar360.com/article/nct02311335-genes-involved-in-lipid-disorders-9ad46f577bcda536Pharma Surgeen2026-07-17T00:00:00.000ZNCT02311335: Genes Involved in Lipid Disordershttps://www.pharmaradar360.com/article/nct02091999-a-study-of-escalating-doses-of-asg-22ce-given-as-monotherapy-in-subj-d5db9982d101f7a5Pharma Surgeen2026-07-17T00:00:00.000ZNCT02091999: A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4https://www.pharmaradar360.com/article/nct01949662-haloperidol-and-lorazepam-for-delirium-in-patients-with-advanced-can-433da61bb77499b4Pharma Surgeen2026-07-17T00:00:00.000ZNCT01949662: Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancerhttps://www.pharmaradar360.com/article/nct00598351-natural-history-study-of-patients-with-neurofibromatosis-type-2-054fcc8a1d804bcdPharma Surgeen2026-07-17T00:00:00.000ZNCT00598351: Natural History Study of Patients With Neurofibromatosis Type 2https://www.pharmaradar360.com/article/nct00481546-phase-i-trial-of-gene-vector-to-patients-with-retinal-disease-due-to-83e049d51ac7af0fPharma Surgeen2026-07-17T00:00:00.000ZNCT00481546: Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutationshttps://www.pharmaradar360.com/article/nct00353158-a-pilot-of-pediatric-adult-study-of-gene-expression-profiling-and-cl-c749dc9f71a7c67ePharma Surgeen2026-07-17T00:00:00.000ZNCT00353158: A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicityhttps://www.pharmaradar360.com/article/nct00091871-a-longitudinal-study-of-familial-hypereosinophilia-fe-natural-histor-5390013a41f0795fPharma Surgeen2026-07-17T00:00:00.000ZNCT00091871: A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progressionhttps://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-ad3bb0127554ec45Pharma Surgeen2026-07-16T23:51:17.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-near-its-52-week-high-0d7608874f80505dPharma Surgeen2026-07-16T23:37:30.000ZIs This Biotech Stock a Buy Near Its 52-Week High?https://www.pharmaradar360.com/article/dimerix-acquires-dmx-652-phase-2-asset-and-strengthens-kidney-disease-pipeline-w-3adb709d6de20136Pharma Surgeen2026-07-16T23:15:02.000ZDimerix Acquires DMX-652 Phase 2 Asset and Strengthens Kidney Disease Pipeline with Non-Dilutive Fundinghttps://www.pharmaradar360.com/article/compounded-glp-1s-why-doctors-worry-and-the-fda-is-cracking-down-ca1632ddd25cbc02Pharma Surgeen2026-07-16T23:06:38.000ZCompounded GLP-1s: Why doctors worry and the FDA is cracking downhttps://www.pharmaradar360.com/article/ups-commits-48-million-to-27-temperature-controlled-cross-dock-facilities-for-ph-1b8c4092b3d25cc8Pharma Surgeen2026-07-16T23:02:55.000ZUPS commits $48 million to 27 temperature-controlled cross-dock facilities for pharma and biotechhttps://www.pharmaradar360.com/article/telix-completes-patient-enrollment-in-tlx591-px-illuccix-japan-phase-3-study-652d771e46157df8Pharma Surgeen2026-07-16T22:15:22.000ZTelix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Studyhttps://www.pharmaradar360.com/article/lilly-offers-up-to-3-8-billion-for-ataibeckley-in-bet-on-god-molecule-found-in-t-a9777e5f3b8af372Pharma Surgeen2026-07-16T22:09:01.000ZLilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venomhttps://www.pharmaradar360.com/article/kolon-tissuegene-slides-20-ahead-of-u-s-tg-c-phase-3-results-286461bd79ed3196Pharma Surgeen2026-07-16T22:00:05.000ZKolon TissueGene Slides 20% Ahead of U.S. TG-C Phase 3 Resultshttps://www.pharmaradar360.com/article/takeda-s-daily-pill-helped-clear-psoriasis-on-palms-and-soles-for-about-70-62e7b49ae0078a87Pharma Surgeen2026-07-16T22:00:00.000ZTakeda’s daily pill helped clear psoriasis on palms and soles for about 70%https://www.pharmaradar360.com/article/how-fda-can-speed-drug-innovation-without-cutting-corners-0cb041e2ab943389Pharma Surgeen2026-07-16T21:59:47.000ZHow FDA Can Speed Drug Innovation Without Cutting Cornershttps://www.pharmaradar360.com/article/fda-approves-merck-s-lipfendra-first-oral-pcsk9-drug-to-match-injectables-f3702a703316050aPharma Surgeen2026-07-16T21:56:17.000ZFDA Approves Merck’s Lipfendra, First Oral PCSK9 Drug to Match Injectableshttps://www.pharmaradar360.com/article/has-pfizer-s-seagen-acquisition-reshaped-the-oncology-landscape-6644d3994e5aa75cPharma Surgeen2026-07-16T21:33:52.000ZHas Pfizer's Seagen Acquisition Reshaped the Oncology Landscapehttps://www.pharmaradar360.com/article/drug-repurposing-stakeholders-say-fda-should-act-within-its-authority-avoid-disi-7d3efdd421815e8fPharma Surgeen2026-07-16T21:18:00.000ZDrug repurposing: Stakeholders say FDA should act within its authority, avoid disincentiveshttps://www.pharmaradar360.com/article/ubs-michael-yee-talks-biotech-m-a-outlook-61ef468ee07cec60Pharma Surgeen2026-07-16T21:08:11.000ZUBS Michael Yee talks biotech M&A outlookhttps://www.pharmaradar360.com/article/cder-plans-new-guidance-on-ai-electronic-safety-report-submissions-and-more-0a026b39d3529857Pharma Surgeen2026-07-16T21:02:00.000ZCDER plans new guidance on AI, electronic safety report submissions, and morehttps://www.pharmaradar360.com/article/briacell-bctx-expands-phase-3-study-with-new-clinical-site-038c504f73cc5325Pharma Surgeen2026-07-16T20:48:45.000ZBriaCell (BCTX) Expands Phase 3 Study with New Clinical Sitehttps://www.pharmaradar360.com/article/fda-accepts-nda-for-axs-12-in-cataplexy-associated-with-narcolepsy-71d1ea296c5c44b0Pharma Surgeen2026-07-16T20:20:45.000ZFDA Accepts NDA for AXS-12 in Cataplexy Associated With Narcolepsyhttps://www.pharmaradar360.com/article/gates-mri-serum-institute-sign-deal-to-manufacture-novel-tb-vaccine-candidate-0d19ba1784d81ee2Pharma Surgeen2026-07-16T20:09:11.000ZGates MRI, Serum Institute sign deal to manufacture novel TB vaccine candidatehttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-16T20:01:06.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/houston-als-biotech-coya-eyes-2028-approval-path-0892964e5a2a9c85Pharma Surgeen2026-07-16T19:51:52.000ZHouston ALS Biotech Coya Eyes 2028 Approval Pathhttps://www.pharmaradar360.com/article/basis-kids-phase-3-trial-releases-encouraging-interim-data-on-marstacimab-for-he-98089931fb4c5642Pharma Surgeen2026-07-16T19:37:00.000ZBASIS KIDS Phase 3 Trial Releases Encouraging Interim Data on Marstacimab for Hemophilia A, Bhttps://www.pharmaradar360.com/article/kalshi-is-letting-people-bet-on-clinical-trials-and-fda-drug-decisions-373241bf22f43a54Pharma Surgeen2026-07-16T19:04:21.000ZKalshi Is Letting People Bet On Clinical Trials And FDA Drug Decisionshttps://www.pharmaradar360.com/article/fact-check-claims-linking-statins-to-dementia-are-false-a262635655c713e5Pharma Surgeen2026-07-16T19:00:16.000ZFact Check: Claims Linking Statins to Dementia Are Falsehttps://www.pharmaradar360.com/article/this-biotech-stock-nearly-doubled-in-value-today-morning-what-s-driving-investor-2b6d85a1f88a0aebPharma Surgeen2026-07-16T18:53:28.000ZThis Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?https://www.pharmaradar360.com/article/news-capricor-signs-san-diego-s-largest-biotech-lease-of-the-year-ac18b9e808e46fa7Pharma Surgeen2026-07-16T18:49:04.000ZNews | Capricor signs San Diego’s largest biotech lease of the yearhttps://www.pharmaradar360.com/article/fda-grants-orphan-drug-designation-to-once-nightly-oxybate-for-idiopathic-hypers-8be1bac7a897abfdPharma Surgeen2026-07-16T18:46:40.000ZFDA Grants Orphan Drug Designation to Once-Nightly Oxybate for Idiopathic Hypersomniahttps://www.pharmaradar360.com/article/fda-approves-lipfendra-pharmexec-4549d309a34b6dbcPharma Surgeen2026-07-16T18:43:45.000ZFDA Approves Lipfendra | PharmExechttps://www.pharmaradar360.com/article/hygiene-safety-lapses-in-production-area-fda-suspends-licence-of-south-mumbai-s-c75ecd40c50fa2caPharma Surgeen2026-07-16T18:42:21.000Z‘Hygiene, safety lapses in production area’: FDA suspends licence of South Mumbai’s iconic 110-year-old Parsi Dairy Farmhttps://www.pharmaradar360.com/article/sii-gates-mri-ink-pact-to-manufacture-new-tb-vaccine-candidate-after-successful-ae8691ced3fc9cb8Pharma Surgeen2026-07-16T18:36:00.000ZSII & Gates MRI ink pact to manufacture new TB vaccine candidate after successful Phase 3 trialshttps://www.pharmaradar360.com/article/serum-institute-gates-medical-research-institute-partners-to-manufacture-new-tb-54a03d60b234d52aPharma Surgeen2026-07-16T18:33:08.000ZSerum Institute, Gates Medical Research Institute partners to manufacture new TB vaccinehttps://www.pharmaradar360.com/article/sii-gates-mri-ink-pact-to-manufacture-new-tb-vaccine-candidate-after-successful-37b652b308cecfd5Pharma Surgeen2026-07-16T18:30:00.000ZSII & Gates MRI ink pact to manufacture new TB vaccine candidate after successful Phase 3 trialshttps://www.pharmaradar360.com/article/eli-lilly-acquires-psychedelics-specialist-ataibeckley-what-investors-should-kno-2a8b87a7229db9dbPharma Surgeen2026-07-16T18:07:18.000ZEli Lilly Acquires Psychedelics Specialist AtaiBeckley - What Investors Should Know (LLY)https://www.pharmaradar360.com/article/nobel-laureate-jennifer-doudna-enters-ai-protein-design-arena-e48311cb4610afbaPharma Surgeen2026-07-16T18:00:00.000ZNobel Laureate Jennifer Doudna enters AI protein design arenahttps://www.pharmaradar360.com/article/eli-lilly-buys-psychedelics-maker-atai-beckley-for-2-8-billion-to-develop-dmt-li-daa99f5d7e338befPharma Surgeen2026-07-16T17:53:41.000ZEli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drughttps://www.pharmaradar360.com/article/mid-year-check-in-will-pharma-m-a-keep-pace-af840a02a921e2a5Pharma Surgeen2026-07-16T17:49:54.000ZMid-Year Check-In: Will Pharma M&A Keep Pace?https://www.pharmaradar360.com/article/the-fda-s-latest-psychedelics-guidance-could-reshape-future-clinical-trials-cb13124a81df0966Pharma Surgeen2026-07-16T17:39:41.000ZThe FDA’s latest psychedelics guidance could reshape future clinical trials